Pfizer to buy Vicuron Pharmaceuticals for $1.9 billion

Share this article:
Pfizer has agreed to acquire biopharmaceutical company Vicuron Pharmaceuticals for $1.9 billion in a move to expand its offerings of anti-infective products.
Vicuron, based in King of Prussia, Pa., has two products currently under new drug application review at the FDA.
The products are anidulafungin for fungal infections and dalbavancin for skin and soft tissue infections. Both have shown positive results in late-stage studies, according to published reports.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.